Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
2.730
-0.220 (-7.46%)
Apr 16, 2026, 5:04 PM CET
Market Cap36.12M -26.1%
Revenue (ttm)n/a
Net Income-17.93M
EPS-4.52
Shares Out12.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume268,566
Average Volume1,121,324
Open2.900
Previous Close2.950
Day's Range2.705 - 2.960
52-Week Range1.353 - 10.450
Beta0.47
RSI53.50
Earnings DateApr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements